3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
255
Rectal Neoplasms
155
Colonic Neoplasms
128
Stomach Neoplasms
100
Pancreatic Neoplasms
94
Breast Neoplasms
77
Esophageal Neoplasms
76
Neoplasm Metastasis
58
Squamous Cell Carcinoma of Head and Neck
56
Head and Neck Neoplasms
56
Neoplasms
43
Adenocarcinoma Of Esophagus
37
Esophageal Squamous Cell Carcinoma
27
Adenocarcinoma
25
Unspecified Adult Solid Tumor, Protocol Specific
15
Carcinoma, Hepatocellular
15
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Anus Neoplasms
12
Keratosis, Actinic
11
Gastrointestinal Neoplasms
11
Biliary Tract Neoplasms
11
Gallbladder Neoplasms
10
Carcinoma, Squamous Cell
10
Urinary Bladder Neoplasms
9
Nasopharyngeal Carcinoma
9
Liver Neoplasms
9
Cholangiocarcinoma
9
Carcinoma
9
Bile Duct Neoplasms
9
Recurrence
8
Interventions
pembrolizumab
3
Nivolumab
2
vicriviroc
1
relatlimab
1
copanlisib
1
binimetinib
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Spinocerebellar Degenerations
×
Fluorouracil
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts